Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis

Arthritis and Rheumatism

Volumn 64, Issue 5, 2012, Pages 1642-1652

  Avouac, Jérôme ^a   Palumbo, Katrin ^a   Tomcik, Michal ^b   Zerr, Pawel ^a   Dees, Clara ^a   Horn, Angelika ^a   Maurer, Britta ^c   Akhmetshina, Alfiya ^a   Beyer, Christian ^a   Sadowski, Anika ^a   Schneider, Holm ^a   Shiozawa, Shunichi ^d   Distler, Oliver ^c   Schett, Georg ^a   Allanore, Yannick ^e   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; BLEOMYCIN; COLLAGEN TYPE 1; FIBRONECTIN; HYDROXYPROLINE; INTERSTITIAL COLLAGENASE; MESSENGER RNA; PROTEIN C FOS; PROTEIN C JUN; SMALL INTERFERING RNA; T 5224; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL STIMULATION; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN FIBROSIS; STRESS FIBER; SYSTEMIC SCLEROSIS; UPREGULATION;

ANIMALS; BENZOPHENONES; BLEOMYCIN; CELLS, CULTURED; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; HUMANS; ISOXAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; PROTO-ONCOGENE PROTEINS C-FOS; RNA, SMALL INTERFERING; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84860464142     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33501     Document Type: Article

References (32)

1. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
2. Allanore Y, Avouac J, Wipff J, Kahan A,. New therapeutic strategies in the management of systemic sclerosis. Expert Opin Pharmacother 2007; 8: 607-15.
3. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
4. Varga JA, Trojanowska M,. Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 2008; 34: 115-43, vii.
5. Varga J, Pasche B,. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5: 200-6.
6. Jochum W, Passegue E, Wagner EF,. AP-1 in mouse development and tumorigenesis. Oncogene 2001; 20: 2401-12.
7. Wagner EF, Eferl R,. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005; 208: 126-40.
8. Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zerr P, et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2010; 62: 280-90.
9. Palumbo K, Zerr P, Tomcik M, Vollath S, Dees C, Akhmetshina A, et al. The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011; 70: 1320-6.
10. Aikawa Y, Morimoto K, Yamamoto T, Chaki H, Hashiramoto A, Narita H, et al. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat Biotechnol 2008; 26: 817-23.
11. LeRoy EC, Medsger TA Jr,. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
12. Woessner JF Jr,. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440-7.
13. Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J, et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008; 58: 2553-64.
14. Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009; 60: 1129-36.
15. Hall MC, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR, et al. The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-β1. J Biol Chem 2003; 278: 10304-13.
16. Goffin L, Seguin-Estevez Q, Alvarez M, Reith W, Chizzolini C,. Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts. Arthritis Res Ther 2010; 12: R73.
17. Beyer C, Schett G, Distler O, Distler JH,. Animal models of systemic sclerosis: prospects and limitations [review]. Arthritis Rheum 2010; 62: 2831-44.
18. Verrecchia F, Tacheau C, Schorpp-Kistner M, Angel P, Mauviel A,. Induction of the AP-1 members c-Jun and JunB by TGF-β/Smad suppresses early Smad-driven gene activation. Oncogene 2001; 20: 2205-11.
19. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, et al. Autoinduction of transforming growth factor β1 is mediated by the AP-1 complex. Mol Cell Biol 1990; 10: 1492-7.
20. Atfi A, Djelloul S, Chastre E, Davis R, Gespach C,. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor β-mediated signaling. J Biol Chem 1997; 272: 1429-32.
21. McGaha TL, Kodera T, Spiera H, Stan AC, Pines M, Bona CA,. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism. Arthritis Rheum 2002; 46: 2748-61.
22. Murao H, Aikawa Y, Hashiramoto A, Yamamoto T, Chaki H, Narita H, et al. A small molecule c-Fos/AP-1 inhibitor T-5224 inhibits osteoclastogenesis and bone resorption [abstract]. Arthritis Rheum 2010; 62 Suppl: S612.
23. Chung KY, Agarwal A, Uitto J, Mauviel A,. An AP-1 binding sequence is essential for regulation of the human α2(I) collagen (COL1A2) promoter activity by transforming growth factor-β. J Biol Chem 1996; 271: 3272-8.
24. Liska DJ, Slack JL, Bornstein P,. A highly conserved intronic sequence is involved in transcriptional regulation of the α1(I) collagen gene. Cell Regul 1990; 1: 487-98.
25. Sherwood AL, Bottenus RE, Martzen MR, Bornstein P,. Structural and functional analysis of the first intron of the human α2(I) collagen-encoding gene. Gene 1990; 89: 239-44.
26. Slack JL, Parker MI, Bornstein P,. Transcriptional repression of the α1(I) collagen gene by ras is mediated in part by an intronic AP1 site. J Cell Biochem 1995; 58: 380-92.
27. Gaedeke J, Noble NA, Border WA,. Curcumin blocks multiple sites of the TGF-β signaling cascade in renal cells. Kidney Int 2004; 66: 112-20.
28. Kim CW, Suh SI, Sung SH, Lee IK, Lee KS,. A transcriptional factor decoy against AP-1 suppresses TGF-β1-induced type I collagen gene expression in cultured keloid fibroblasts. J Dermatol Sci 2005; 37: 49-51.
29. Hocevar BA, Brown TL, Howe PH,. TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 1999; 18: 1345-56.
30. Philips N, Bashey RI, Jimenez SA,. Increased α1(I) procollagen gene expression in tight skin (TSK) mice myocardial fibroblasts is due to a reduced interaction of a negative regulatory sequence with AP-1 transcription factor. J Biol Chem 1995; 270: 9313-21.
31. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
32. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005; 437: 369-75.